Articles from Singlera Genomics, Inc.

LA JOLLA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, with their partner Breakthrough Genomics, a leader in the clinical analysis of genomic data and early cancer diagnostics, today announced a research collaboration with the University of Pittsburgh (Pitt) to advance the preclinical evaluation of Singlera and Breakthrough’s BT-Reveal™ Early Pancreatic Cancer Test.

SAN DIEGO and SHANGHAI, China, June 17, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a biotechnology company focused on non-invasive early cancer detection, and Fudan University’s Zhongshan Hospital, a premier highly ranked public hospital in China, today announced the publication of a peer-reviewed manuscript in the journal Molecular Cancer demonstrating the results of the large-scale multi-center GUIDE prospective cohort study, showing that Singlera’s GutSeer® assay can non-invasively detect five major types of gastrointestinal cancer at early stage using a simple blood test. Some results from the study had previously been presented at the ASCO Annual Meeting held June 2025 in Chicago, Illinois.

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics presented results showing a refined approach to detect drug-induced testicular toxicity using Singlera’s cell-free DNA methylation technology with Astellas during the SOT 2025 Annual Meeting.

SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the application of novel DNA methylation technologies to genetic diagnosis, presented the results of its initial preclinical study of the PDACatch test, an assay to detect pancreatic cancer in individuals at high risk for the disease, at the HM Hospitals annual Hyper-early Diagnosis in Oncology and its Clinical Management meeting.